Zach Klaassen welcomes Vitaly Margulis to discuss the ENLIGHTED trial, a phase three study addressing low-grade upper tract urothelial carcinoma. Dr. Margulis explains the necessity of the trial by highlighting the common over-treatment of this cancer type due to the limited and challenging endoscopic management options available. The trial focuses on Vascular Targeted Photodynamic therapy…
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure,…
Alicia Morgans interviews Omar El-Taji and Ashwin Sachdeva about their JAMA Oncology publication on cardiovascular risks associated with androgen receptor signaling inhibitors (ARSIs) in prostate…
Zach Klaassen and Alicia Morgans discuss the findings from an exploratory analysis of the ARAMIS trial, focusing on the efficacy of darolutamide for non-metastatic castration-resistant…
Ruchika Talwar hosts Daniel Triner to discuss a study on the management of lymph node-positive prostate cancer after radical prostatectomy. Using data from the Michigan…
Dr. Alex Channon currently is a Senior Lecturer in Physical Education and Sport Studies at the University of Brighton, UK. He teaches on undergraduate courses,…
Stanford University scientists’ findings in mice could translate into a radical, needle-free vaccination approach that would also eliminate reactions including fever, swelling and pain.
Axel Heidenreich discusses the final results of the COTRIMS trial, evaluating retroperitoneal lymph node dissection (RPLND) for clinical stage IIA and IIB seminomas. The study…
Veda Giri discusses her roles as director of the Cancer Genetics and Prevention Program and the Early-Onset Cancer Program at Yale Cancer Center, highlighting her…
Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR).…
The incidence of MASH is on the rise. Learn more about determining risk in your patients and the new and emerging therapies available.
